SPTBN1 and hepatocellular carcinoma: We have reported that the absence of SPTBN1 in hepatocellular carcinoma can activate Wnt pathways by downregulating kallistatin [6], while kallistatin increases apoptosis in breast cancer cells by inhibiting miR-203 and enhancing SOCS3 levels via PKC-ERK signaling [38].